


PITER - HCV Cohort





Data collected from 2014 to 2023	N.
Enrolled patients	12.419
From 2014 to 2016	9.358
From 2017 to 2023	3.061
Patients with at least 1 follow-up	9.730
Patients with a DAA therapy	7.043
Patients with at least 1 follow-up post therapy	5.614
Median FU time from the end of treatment	27 months
Range FU time from the end of treatment	3-101 months
Patients lost to follow-up	1129
Deceased patients	203

PITER - HCV Cohort

STAGE OF FIBROSIS IN DAA TREATED PATIENTS



Baseline characteristics of SOF/VEL, GLE/PIB and ELB/GRA treated HCV+ patients



PITER-HBV/HDV Cohort


All patients with HBsAg positivity for at least 6 months with or without co-infection with HDV and/or HCV and/or HIV who are consecutively observed in the participating clinical centers in a given time span (approximately 6 months), independently of antiviral treatment at the time of enrolment.

Data collected from 2019 to March 2024	N.
Enrolled patients from November 2019 to March 2024	5923
Anti-HDV screened	4445
Anti-HDV positive	513
Participating Centers	58


In progress:

- Enrollment
- Update of annual follow-up

STAGE OF FIBROSIS IN HBV AND HBV/HDV PATIENTS



HDV infection by age groups and Country of birth




Italian natives:

Median age **59** years (IQR 54-66 years)

Non-Italian natives:

Median age **45** years (IQR 37-55 years)

HDV infection by Country of birth and gender






Characteristics of HDV coinfectd vs HBV monoinfected patients

Variables	Anti-HDV Positive N = 422	Anti-HDV Negative N = 3730	P-Value
Cirrhosis	299 (70.8)	892 (23.9)	<0.001
Esophageal varices	88 (20.85)	153 (4.10)	<0.001
Previous bleeding	13 (3.08)	28 (0.75)	<0.001
Ascites	34 (8.06)	58 (1.55)	<0.001
Encephalopathy	13 (3.08)	27 (0.72)	<0.001
Portal thrombosis	10 (2.37)	22 (0.59)	<0.001
Child-Pugh			
A	251 (84.0)	791 (88.7)	0.005
B	41 (13.7)	99 (11.1)	
C	7 (2.3)	2 (0.2)	
HCC	42 (10.2)	106 (2.9)	<0.001
HBV DNA positive	115 (29.1)	1330 (36.5)	0.004

Comorbidities in patients with HDV active infection

- Comorbidities were present in 47% of anti-HDV+ patients: younger (<55 years) had higher frequency of psychiatric disorders whereas older pts of overweight/obesity, autoimmune disorders and digestive disease.
- More than one comorbidity were present in 39% of anti-HDV + patients.
- Comorbidities were present in 51% of Italian vs 41% of non-Italian anti-HDV positive patients (P = 0.05).
- 47% of HDV RNA+ patients were eligible to peg-IFN; 41% and 13% had absolute or relative contraindication.



Liver Disease stage and co-factors for disease progression in HDV RNA positive vs HDV RNA negative patients

Variables	HDV RNA+ N = 165 (63.2%)	HDV RNA – N = 96 (36.8%)	P-Value
Cirrhosis	125 (75.8)	61 (63.5)	0.035
Child-Pugh			
A	106 (84.8)	59 (96.7)	0.028
B	18 (14.4)	2 (3.3)	
C	1 (0.8)	0 (0.0)	
Complications of cirrhosis*	45 (36.0)	14 (22.9)	0.073
HCC	25 (15.3)	3 (3.2)	0.003
HBV DNA+	45 (29.0)	27 (28.7)	0.958

Variables	HDV RNA+ N = 165 (63.2%)	HDV RNA – N=96 (36.8%)	P-Value
Potential disease co-factors			
Ongoing alcohol use	19 (13.6)	19 (21.8)	0.175
Past use	20 (14.3)	15 (17.2)	
Diabetes	12 (7.3)	8 (8.3)	0.811
BMI 25-30	38 (23.0)	30 (31.2)	0.007
BMI ≥30	9 (5.4)	14 (14.6)	
Anti-HCV +	13 (8.4)	9 (10.2)	0.647
Anti-HIV +	3 (2.2)	2 (2.4)	>0.999
Ongoing NUC	130 (78.8)	66 (68.8)	0.071
Years of NUC	4.0 (2.0-7.2)	5.5 (1.2-9.2)	0.220